Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| MDA-MB-134-VI | Cediranib | 0.031623 | VEGFR/cKIT | RTK | 1.1450 | 0.00629 |
| CAL-51 | Cediranib | 0.001 | VEGFR/cKIT | RTK | 1.0226 | -0.00124 |
| MDA-MB-134-VI | Cediranib | 3.1623 | VEGFR/cKIT | RTK | 0.8930 | 0.03528 |
| MDA-MB-134-VI | Cediranib | 10.0 | VEGFR/cKIT | RTK | -0.9999 | 0.83082 |
| MDA-MB-134-VI | Cabozantinib | 0.001 | VEGFR2/MET | RTK | 1.3562 | -0.00502 |
| MDA-MB-134-VI | Cabozantinib | 0.01 | VEGFR2/MET | RTK | 1.2226 | -0.01215 |
| MDA-MB-134-VI | Cabozantinib | 0.1 | VEGFR2/MET | RTK | 1.2207 | -0.00515 |
| MDA-MB-134-VI | Cabozantinib | 1.0 | VEGFR2/MET | RTK | 1.3646 | -0.00006 |
| MDA-MB-134-VI | Cabozantinib | 3.1623 | VEGFR2/MET | RTK | 1.2303 | -0.00662 |
| MCF 10A | Neratinib | 0.031623 | EGFR/HER2 | RTK | 0.7332 | -0.00632 |